ASX & MEDIA RELEASE **14 MARCH 2019**

NANABIS™ UPDATE: "THE JOURNEY FROM CANNABIS TO A REGISTERED DRUG"

- **Medlab CEO, Dr Sean Hall last night, presented a clinical NanaBis™ update to Medical Practitioners as part of on-going medical education**
- **Data, very encouraging – safe, tolerable, repeatable**
- **Regulatory pathways are solid**

Australian medical life sciences company, Medlab Clinical Ltd (ASX: MDC) is pleased to announce further strong data resulting from both clinical trial and approved Government Special Access Scheme (SAS) use.

As part of MDC's ongoing medical education, Dr Hall presented to medical practitioners last night where he explained several key aspects of NanaBis™ highlighted by recent work, these included:

1/. Beyond the Stage 1 Advanced Cancer Pain Trial Results
Further to previously announced Stage 1 results, NanaBis™ data from that component of the trial was directly compared to published data for an ARTG approved Cannabis Drug. The head to head comparison demonstrates a similar plasma level of THC and CBD with NanaBis being half the dose. Similarly, the rate of absorption for NanaBis™ was faster.

2/. NanaBis™ Case Studies
Several case studies for NanaBis™ use under SAS were discussed. A summary of 5 individual case studies from 5 different Doctors were provided, see summary below.

Consent for use was obtained via the prescribing Doctor.

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Age	87	69	57	42	51
Gender	F	F	M	M	M
Condition	Severe chronic pain	Severe chronic back pain	Chronic pain	Fibromyalgia and Chronic Fatigue Syndrome	Neuropathic pain
Medication(s) pre NanaBIs™	1. Diazepam 2. Pregablin 3. Meloxicam 4. Oxycodone 5. Tramadol	1. Panadeine Forte 2. Tapentadol 3. Pregablin 4. Meloxicam 5. Oxycodone Tramadol	1. Mersyndol	1. Paracetamol 2. Ibuprofen 3. Voltaren 4. Panadeine Forte 5. Oxycodone IR	1. Oxycontin 2. Panadeine Forte
Medications post NanaBis™	Ceased all other medications after 1 month	Significant reduction in other medications after 2 weeks	Significant reduction in opioids after 10 days	Ceased all other medications after 4 days.	Ceased all other medications. Patient found pain relief within the first few days.
Symptoms	Pain score reduced from 9/10 to 2/10 (low as 1/10)	Pain score reduced from 10/10 to 4/10	Patient reports better quality of sleep	Pain score reduced from 10/10 to 4/10	Pain score reduced from 9/10 to 4/10

The data (a small cross section of NanaBis™ use, collected via the SAS) shows:

- Significant improvements in quality of life inclusive of sleep and movement with reduced pain/restriction
- The reduction/replacement of previously prescribed medication (in particular opioids).
- Reduction in pain severity scores.
- Reduction of symptoms

3/. Regulatory Approach – articulated pathways

Based on trial activity, Medlab is actively pursuing regulatory pathways for Therapeutic Goods Association (TGA) in Australia, Federal Drug Administration (FDA) in USA and the European Medicines Agency (EMA). Medlab has a planned framework that should take NanaBis™ to an approved drug.

Summary

In short, Medlab is extremely pleased with the pooled data collected to date as well as the ongoing regulatory pathway for an approved drug.

ISSUED FOR:	**MEDLAB CLINICAL LTD (ASX: MDC) – www.medlab.co**
FOR FURTHER INFORMATION:	**DR SEAN HALL, CEO, MEDLAB CLINICAL** **TEL: +61 2 8203 9520, sean_hall@medlab.co**
ISSUED BY:	HILL + KNOWLTON STRATEGIES, MARCHA VAN DEN HEUVEL TEL +61 2 9286 1226 OR +61 468 960 457, marcha.vandenheuvel@hkstrategies.com

ABOUT MEDLAB – www.medlab.co

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, Nanocelle™, is being applied to its medicines, nutritional products and off-patent drugs like statins. Medlab has a growing patent portfolio.